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Summary: 
The strong association of CD4 count at start of combination therapy with subsequent survival in HIV 
positive patients diminished during the first five years of treatment. After five years, lower baseline 
CD4 counts were not associated with higher mortality. 
 
Abstract 
 
Background: CD4 count at start of combination antiretroviral therapy (ART) is strongly associated 
with short-term survival, but its association with longer-term survival is less well characterised. 
 
Methods: We estimated mortality rates (MR) by time since start of ART (<0.5, 0.5-0.9, 1-2.9, 3-3.9, 5-
9.9 and ≥10 years) among patients from 18 European and North American cohorts who started ART 
during 1996-2001. Piecewise exponential models stratified by cohort were used to estimate crude 
and adjusted (for sex, age, transmission risk, period of starting ART [1996-7, 1998-9, 2000-1], AIDS 
and HIV-1 RNA at baseline) mortality rate ratios (MRR) by CD4 count at start of ART (0-49, 50-99, 
100-199, 200-349, 350-499, ≥500 cells/μL) overall and separately according to time since start of 
ART.  
 
Results: 6,344 of 37,496 patients died during 359,219 years of follow up. The MR per 1000 person-
years was 32.8 (95% CI 30.2-35.5) during the first 6 months, declining to 16.0 (15.4, 16.8) during 5-
9.9 years and 14.2 (13.3-15.1) after 10 years duration of ART. During the first year of ART there was a 
strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 
4 years. The adjusted MRR per CD4 group were 0.97 (0.94-1.00), p=0.054 and 1.02 (0.98-1.07), 
p=0.32 among patients followed for 5-9.9 and >10 years respectively.  
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Conclusions: After surviving five years of ART, the mortality of patients who started ART with low 
baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 
counts.  
 
 
Introduction 
Combination antiretroviral therapy (ART) based on three or more antiretroviral drugs including 
either a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase 
inhibitor (II) has substantially improved the prognosis of HIV-1 positive patients since its introduction 
in high income settings in 1996 (1). ART suppresses HIV-1 replication, leading to declines in plasma 
HIV-1 RNA, increased CD4 T-cell counts and eventually decreased morbidity and mortality (2). 
Because patients have now been treated with ART for up to 20 years, it is of major interest to 
explore predictors of long-term prognosis.  
The Antiretroviral Therapy Cohort Collaboration (ART-CC) was initiated in 2000 by investigators from 
HIV cohort studies in North America and Europe, in order to assemble datasets that were sufficiently 
large to study the prognosis of HIV-1 positive patients who started ART. Prognostic models that 
estimated 3 and 5 year survival were published in 2002 and 2007 (3, 4) and showed CD4 count at 
start of ART (baseline) to be the strongest predictor of short-term mortality. However, baseline CD4 
count becomes less prognostic when 6 month response to treatment is taken into account (5). HIV-1 
viral load at 6 months and changes in CD4 count from 6 to 36 months after start of ART are 
prognostic for AIDS in patients who have survived three years of ART (6). 
To date short-term prognosis has been extrapolated to predict long-term disease-free survival (7, 8). 
Since mortality in the general population varies by age, sex and country of residence, estimates of 
mortality rate ratios (MRR) may be more informative when corrected for background mortality (9). 
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We investigated how long patients bear the burden of increased mortality due to starting ART with 
low CD4 counts, by studying the prognostic value of baseline CD4 count for mortality up to 15 years 
after start of ART, using both standard survival analysis models and models for relative survival. 
 
Methods 
Study sample 
The Antiretroviral Therapy Cohort Collaboration (ART-CC), which is described in detail elsewhere 
(http://www.art-cohort-collaboration.org) (10), is an international collaboration of HIV cohort 
studies from North America and Europe that combines data on HIV-positive individuals aged 16 
years or older who were antiretroviral-naïve when they started ART with a combination of at least 
three drugs. Eligible regimens include at least one PI, NNRTI or II and two nucleoside-analogue 
reverse-transcriptase inhibitors (NRTI). The present study included data from eighteen cohorts, 
which are listed in the appendix. All were approved by local ethics committees. The NHS Health 
Research Authority South West - Cornwall and Plymouth Research Ethics Committee, UK, approved 
the study (REC reference 12/SW/0253). The data used here included follow up from 1996 until 31st 
July 2013. We included patients who started ART between 1996 and 2001 (so had at least 12 years’ 
potential follow up) and had at least one available baseline (within 3 months prior to starting ART) 
measurement of CD4 count and viral load. 
Statistical analysis 
We categorised CD4 counts into six groups (0-49, 50-99, 100-199, 200-349, 350-499 and ≥500 
cells/μL); viral loads into three groups (0-9,999, 10,000-99,999 and ≥100,000 copies/μL); age at 
baseline into five groups (16-29, 30-39, 40-49, 50-59 and 60 years or over); year of starting ART into 
three groups (1996-7, 1998-9, 2000-1); and ART regimen into 5 groups (NNRTI-based, PI-based,  NRTI 
including abacavir, other NRTI not including abacavir, and other regimens). Patients were followed 
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up from the date of starting ART (“baseline”) to the earliest of the date of death, lost to follow-up 
(LTFU) or administrative censoring. Patients were considered lost to follow up (LTFU) at their last 
clinical observation if it was over a year before the cohort specific close date of the database. Data 
were analysed as intent-to-continue-treatment, ignoring treatment changes and interruptions. 
We used unadjusted (Kaplan-Meier) and adjusted estimates of cumulative mortality to examine 
whether CD4 count at start of ART was prognostic for mortality. The adjusted estimates were for a 
typical patient: MSM aged 30-39 years, who started ART between 1998 and 1999 in the FHDH cohort 
in France without a diagnosis of AIDS, and with high viral load (HIV-1 RNA > 100,000). We used 
Poisson models to estimate crude mortality rates (MR) with 95% confidence intervals (CI), for all 
patients and by baseline CD4 count. We then estimated MRs separately according to duration of 
time on ART (<0.5, 0.5-0.99, 1-2.99, 3-4.99, 5-9.99 and ≥10 years after ART start), overall and by 
baseline CD4 count. We used Cox models stratified by cohort to estimate crude and adjusted (for 
sex, age, transmission risk group, AIDS at baseline, baseline viral load, and year of starting ART) 
mortality rate ratios (MRR) by baseline CD4 group with 200-349 cells/μL as the reference category, 
overall and separately according to time on ART. Relative survival models based on generalized 
linear models (modified Poisson models) were used to account for variation in background 
population mortality (11). Expected death rates for each country split by sex and 5-year age group 
were obtained from the Human Mortality Database (www.mortality.org). We estimated adjusted 
(for the same set of covariates) relative MRR, overall and according to duration of time on ART. The 
prognostic value of baseline CD4 count according to time since start of ART was compared by 
estimating the adjusted MRR per CD4 count category (assuming a log-linear relationship with 
mortality rate across the CD4 categories). All analyses were performed using Stata version 13 
(StataCorp, Texas, USA).  
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Results  
A total of 37,496 patients started ART between 1996 and 2001 and were eligible for analyses. The 
majority were male, with median age at start of ART 37 (IQR 31 to 44) years (table 1). Median follow-
up time was 11.3 years (IQR 5.6 to 13.4 years) with 28,947 (77%) of patients having at least 5 years 
and 21,936 (58%) more than 10 years’ follow-up. Numbers of patients at risk by duration of ART and 
baseline CD4 count are shown in web table 1. The risk transmission group distribution reflected the 
early HIV epidemic, with similar proportions of men who have sex with men (MSM) and 
heterosexually infected patients, and 20% infected via injection drug use (IDU). The median baseline 
CD4 count was 221 (IQR 86 to 376) cells/μL: 17,077 (46%) patients started ART with CD4 count <200 
cells/μL and 10,278 (27%) with CD4 count <100 cells/μL. Compared with patients who started ART 
with CD4 count <350 cells/μL, those who started with higher CD4 count were more likely to be MSM 
and to have started ART in 1997-99, and were slightly younger on average. The majority of patients 
(24,313 (65%)) started on a PI-based regimen, whilst 10,146 (27%) started on a NNRTI-based 
regimen. The rate of LTFU was 0.04 per year. 
There were 6,344 deaths during 359,219 years of follow up. Baseline CD4 count was highly 
prognostic for unadjusted cumulative mortality in all patients (figure 1). Baseline CD4 count was also 
highly prognostic for adjusted cumulative mortality which is illustrated (figure 2) for a typical patient 
group (MSM in the FHDH cohort, aged 30-39 years, who started ART between 1998 and 1999 
without a diagnosis of AIDS, and with high viral load (HIV-1 RNA > 100,000)). There is a clearly graded 
increase in mortality with decreasing baseline CD4 count: cumulative 15-year mortality varied from 
7.1% (95% CI 2.9% to 11.3%) for baseline CD4 count >500 cells/μL to 10.7% (95% CI 4.7% to 16.7%) 
for baseline CD4 count <50 cells/μL. A table showing the corresponding numbers at risk for figure 1 
at different time points split by CD4 count is available from the authors on request. 
Numbers of deaths and crude mortality rates per 1000 person years, according to baseline CD4 
count and time since start of ART are shown in table 2. Overall mortality per 1000 person years 
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declined from 33 (95% CI 30 to 36) during the first 6 months of ART to 14 (95% CI 13 to 15) among 
those who survived 10 years from start of ART, despite the aging of the study population over this 
period. Patients who started ART with a CD4 count below 50 cells/μL experienced the greatest 
declines in mortality rates over time on ART, from 88 (95% CI 78 to 99) per 1000 person years during 
the first 6 months to 15 (95% CI 13 to 17) after 10 years from start of ART. Although mortality rates 
were strongly inversely associated with baseline CD4 counts at shorter times since start of ART, the 
magnitude of these associations diminished with increasing duration of ART. Beyond 10 years of 
ART, there was little evidence of differences in crude mortality rates according to CD4 count at start 
of ART.  
Table 3 shows associations of CD4 count at start of ART with mortality at different durations since 
start of ART and averaged over all follow up time, estimated from crude, adjusted and relative 
survival models. Estimates are presented as MRR with 95% CIs, with CD4 200-349 cells/μL as the 
comparator group. As expected crude, adjusted and relative mortality rate ratios averaged over all 
follow-up time decreased with increasing CD4 count at start of ART. After adjusting for other 
prognostic factors, the MRR comparing baseline CD4 count <50 with 200-349 cells/μL during the first 
6 months of ART was 2.81 (95% CI 2.12 to 3.71): this declined to 1.59 (95% CI 1.31 to 1.92) 3-4.9 
years after start of ART. During the first 5 years of ART, rate ratios comparing patients whose 
baseline CD4 count was greater than 350 cells/ μL with 200-349 cells/μL were less than 1. However 
there was little evidence that baseline CD4 count was prognostic for mortality after 5 years of ART 
since the adjusted MRRs per CD4 category were 0.97 (95% CI 0.94 to 1.00, p=0.054) and 1.02 (95% CI 
0.98 to 1.07, p=0.32) among patients followed for 5-9.9 and ≥10 years, respectively. Adjusted 
relative MRRs were generally further from 1 than the corresponding adjusted MRRs indicating that 
failing to account for expected mortality partially obscured the association of CD4 count with 
mortality risk. Differences between the two analyses diminished with increasing time on ART 
because the strength of the association of mortality with baseline CD4 count also decreased with 
time. 
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Discussion 
In our collaborative analysis of 37,496 HIV-positive patients from 18 cohorts starting triple 
combination ART between 1996 and 2001 there was a strong inverse association of CD4 count with 
mortality during the first year of ART which diminished over the next 4 years. From 5 years after 
start of ART, baseline CD4 count was of little prognostic value. Even patients who started ART with 
very low (< 50 cells/μL) CD4 counts may experience convergence of their mortality risk to that of 
patients  with intermediate (200-349 cells/μL) or high (≥ 500 cells/μL) baseline CD4 count, from 5 
years after the start of treatment.  As expected, associations of baseline CD4 count with mortality 
were attenuated after adjusting for other prognostic factors at the time of starting ART. Associations 
moved away from the null after further adjusting for background mortality in relative survival 
models, but this did not impact our results substantially. 
The importance of CD4 count nadir as a prognostic factor for survival in HIV-positive individuals 
starting ART is well-established (3). However, the extent to which patients with low baseline CD4 
count surviving the first years of treatment remain at an increased risk of death, compared to 
patients starting with higher baseline CD4 counts has remained unclear. To our knowledge, our 
study is the first to demonstrate that patients who started treatment in later stages of HIV disease 
may expect their mortality risk to become similar to that of patients starting treatment with higher 
CD4 counts, if they survive the first five years of therapy. The majority of patients 85.7% (95% CI 85.2 
to 86.3%) that started ART with CD4 count below 200 cells/mm³ in this cohort collaboration do 
indeed survive 5 years. This is an important message for patients and physicians alike, as the moving 
from a higher to a lower risk group through long-term treatment adherence may be a powerful 
motivator. Our findings are consistent with previous studies which showed that current is more 
important than baseline CD4 count (5, 6).  
For the first five years of ART there was a graded inverse relationship between baseline CD4 count 
and mortality, which was consistent with our previous findings (12). After five years of ART, more 
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than 15% of the patients with a baseline CD4 count of less than 50 cells/μL had died. These results 
are consistent with the rate of immunological non-responders to ART previously observed (13, 14). 
Patients with poor immunological response or multiple AIDS or non-AIDS morbidity continue to have 
a substantially increased mortality ratio after three years of treatment (14, 15). A low CD4 nadir is 
not only an established risk factor for death, but also for poor CD4 recovery (16-18). This may reach 
a plateau after about two years of ART (18), although a very recent analysis indicates slow but steady 
long-term recovery of CD4 counts under continued treatment (15). 
These findings raise the question of how to identify patients at high risk of mortality during the first 
five years of ART and what strategies could reduce this risk. These could include screening programs 
and intensive adherence counselling. A previous study demonstrated that patients with less than 
200 CD4 cells/μL at baseline are at a higher risk especially for AIDS- but also for non-AIDS-related 
mortality (12). In that study, malignancies and infections were the primary causes of death, and both 
occurred more frequently in patients with less than 200 CD4 cells/μL. The observed convergence of 
survival rates after five years may be partly explained by the early death of patients with low to very 
low baseline CD4 count, especially immunological non-responders, while others gradually achieve 
immunological recovery. The suggestion of a lower risk amongst those who started ART with very 
low compared with intermediate CD4 count after 10 years may reflect a survivor cohort who are 
adherent and respond well to therapy, but is also consistent with a chance finding. 
We analysed large numbers of patients from high quality clinical cohorts. We obtained more 
accurate comparisons by using relative survival models which adjust for both patient characteristics 
and the background age, sex and country general population mortality. Adjusting associations of CD4 
count with mortality for age and sex as covariates in a conventional analysis which only considers 
mortality of those with HIV infection may be inducing bias towards the null. Whilst additionally 
adjusting for background mortality increased associations of baseline CD4 count with both 
cumulative mortality and early mortality, it did not affect our conclusions about the convergence of 
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mortality in those who survived five years from starting ART. Our study has some limitations. We 
chose patients starting ART between 1996 and 2001 to allow ten years or more of follow-up for each 
person included. While only such patients have been treated with long term ART, newer drugs that 
have been introduced since 2002 are associated with better immune recovery (19) and/or CD4 
recovery in immunological non-responders (19-21), compared with drugs on which the patients in 
our study started combination ART. More second line treatment options and new formulations with 
improved convenience have become available, allowing better treatment adherence and successful 
treatment of drug resistant infections. Therefore, patients across all baseline CD4 count strata are 
likely to experience lower mortality than for the patients included in our study.  
While we included a broad range of patients with different risk factors from Europe and North 
America, generalizability to patients treated in other settings may be limited. Our results may be 
biased by LTFU. Although LTFU rates were high, cohorts have good ascertainment of death 
procedures and it is therefore more likely that patients transferred care to another centre not in 
ART-CC or dropped out of care, rather than died (22). However, our results should be generalizable 
to individuals remaining in HIV care. The high death rate observed in patients with unknown risk 
transmission is linked to the high death rate in older patients because risk group was poorly 
recorded in cohorts that included more patients aged over 60 years. Data on non-HIV related 
factors, for example socio-economic disadvantage or lifestyle risk factors, were not available, but 
may have contributed to excess mortality during the first five years of treatment in patients with low 
baseline CD4 counts.  
In conclusion, CD4 count at start of ART strongly predicts mortality rates during the first five years’ of 
ART. This finding reinforces the need for earlier diagnosis and treatment of people living with HIV. 
However, there is little evidence that CD4 count at start of ART predicts mortality after five years of 
ART. This is a positive message for patients: the burden of increased mortality associated with 
starting treatment late is alleviated for those who survive five years on ART.
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Cohort Study (HAVACS), USA; Osterreichische HIV-Kohortenstudie (OEHIVKOS), Austria; Proyecto 
para la Informatizacion del Seguimiento Clinico-epidemiologico de la Infeccion por HIV y SIDA 
(PISCIS), Spain; University of Washington HIV Cohort, USA; VACH, Spain; Veterans Aging Cohort 
Study (VACS), USA; Vanderbilt, USA and the Koln/Bonn Cohort. 
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Figure 1: Unadjusted estimates of overall cumulative mortality by CD4 count at start of ART.  
 
Figure 2: Adjusted estimates of cumulative mortality by CD4 count at start of ART for a typical patient group 
(MSM aged 30-39 years, who started ART between 1998 and 1999 without a diagnosis of AIDS, with high 
viral load (HIV-1 RNA > 100,000) from the FHDH cohort based in France). 
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Table 1: Demographic and clinical characteristics at start of ART (N = 37,496) 
Year of starting ART Number of patients (%) Deaths (%) 
1996 - 97 8,304 (22%) 1,550 (19%) 
1998 - 99 15,599 (42%) 2,760 (18%) 
2000 - 01 13,593 (36%) 2,034 (15%) 
Female 8,293 (22%) 817 (10%) 
AIDS at start of ART 8,516 (23%) 2,103 (25%) 
CD4 count/µL Median: 221, IQR (86, 376)  
0 - 49 6,512 (17%) 1,654 (25%) 
50 - 99 3,766 (10%) 844 (22%) 
100 - 199 6,799 (18%) 1,292 (19%) 
200 - 349 9,633 (26%) 1,338 (14%) 
350 - 499 5,990 (16%) 697 (12%) 
≥500 4,796 (13%) 519 (11%) 
HIV-1 RNA (copies/µL) Median: 75,000, IQR (18,000, 239,000)  
0 - 9,999 6,834 (18%) 843 (12%) 
10,000 - 99,999 14,149 (38%) 2,186 (15%) 
≥100,000 16,513 (44%) 3,315 (20%) 
Age (years) Median: 37, IQR (31,44)  
16-29 6,734 (18%) 514 (8%) 
30-39 16,572 (44%) 2,094 (13%) 
40-49 9,104 (24%) 1,989 (22%) 
50-59 3,766 (10%) 1,184 (31%) 
≥60  1,320 (4%) 563 (43%) 
Risk transmission group    
MSM 11,067 (30%) 1,056 (10%) 
Injection drug use 7,626 (20%) 1,625 (21%) 
Heterosexual 11,709 (31%) 1,122 (10%) 
Blood 440 (1%) 77 (18%) 
Other or unknown 6,654 (18%) 2,464 (37%) 
Length of follow-up (years) Median: 11.3, IQR (5.6, 13.4)  
Regimen   
NNRTI-based 10,146 (27%) 1,559 (15%) 
PI-based 24,313 (65%) 4,371 (18%) 
Triple NRTI (including 
abacavir) 
2,006 (5%) 240 (12%) 
Other-NRTI 760 (2%) 112 (15%) 
Other 271 (1%) 62 (23%) 
IQR inter-quartile range 
MSM men who have sex with men 
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Table 2: Numbers of deaths and crude mortality rates (95% CI) per 1000 person years by CD4 count at start of ART and duration of follow-up. (6314 deaths overall) 
 Duration of follow up from start of ART (years) 
  < 0.5  0.5-0.99 1-2.99 3-4.99 5-9.99 ≥ 10 
N patients  37,496 35,928 34,841 31,185 28,944 21,931 
CD4 at ART 
start 
(cells/µL) 
N MR (95% CI) N MR (95% CI) N MR (95% CI) N MR (95% CI) N MR (95% CI) N MR (95% CI) 
0 - 49 275 88 (78.2, 99.0) 145 48.9 (41.6, 57.5) 414 38.1 (34.6, 42.0) 275 28.4 (25.3, 32.0) 381 18.6 (16.8, 20.6) 164 14.8 (12.7, 17.2) 
50 - 99 84 45.8 (37.0, 56.7) 64 36.5 (28.5, 46.6) 181 27.9 (24.1, 32.2) 143 24.4 (20.7, 28.8) 258 21.1 (18.7, 23.9) 114 17.8 (14.8, 21.4) 
100 - 199 115 34.7 (28.9, 41.7) 82 25.7 (20.7, 31.9) 261 21.9 (19.4, 24.7) 224 20.7 (18.2, 23.6) 426 18.9 (17.2, 20.8) 184 15.8 (13.7, 18.3) 
200 - 349 75 15.9 (12.6, 19.9) 62 13.5 (10.5, 17.4) 221 12.7 (11.2, 14.5) 248 15.5 (13.7, 17.6) 490 14.6 (13.4, 16.0) 242 13.6 (12.0, 15.4) 
350 - 499 30 10.2 (7.1, 14.6) 22 7.7 (5.0, 11.6) 96 8.8 (7.2, 10.7) 122 12 (10.1, 14.4) 288 13.3 (11.9, 14.9) 139 11.5 (9.7, 13.6) 
≥ 500 20 8.5 (5.4, 13.2) 10 4.3 (2.3, 8.1) 73 8.4 (6.6, 10.5) 79 9.8 (7.9, 12.2) 206 11.9 (10.4, 13.6) 131 13.5 (11.4, 16.1) 
ALL 599 32.8 (30.2, 35.5) 385 21.8 (19.7, 24.1) 1246 18.8 (17.8, 19.9) 1091 18.0 (17.0, 19.1) 2049 16.0 (15.4, 16.8) 974 14.2 (13.3, 15.1) 
MR Mortality Rate; CI Confidence Interval
 at U
niversity Library on A
pril 12, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
Table 3: Crude and adjusted associations of CD4 count at start of ART with mortality at increasing durations 
since start of ART. The relative survival model accounts for age, sex and country matched population 
mortality.  
    CD4 count (cells/µL) 
    0-49 50-99 100-199 200-349 350-499 ≥500 
  
N 
(Deaths) 
6,512 (1,654) 3,766 (844) 6,799 (1,292) 
9,633 
(1,338) 
5,990 (697) 4,796 (519) 
D
u
ra
ti
o
n
 o
f 
A
R
T 
(y
e
ar
s)
 
  Crude mortality rate ratios (95% CI) 
<0.5 5.51 (4.26, 7.12) 2.92 (2.14, 3.99) 2.22 (1.66, 2.97) 1 0.63 (0.41, 0.96) 0.53 (0.32, 0.87) 
0.5-0.9 3.47 (2.57, 4.68) 2.71 (1.91, 3.84) 1.92 (1.38, 2.67) 1 0.56 (0.34, 0.91) 0.32 (0.17, 0.63) 
1-2.9 2.85 (2.42, 3.36) 2.16 (1.78, 2.63) 1.72 (1.44, 2.06) 1 0.69 (0.54, 0.86) 0.67 (0.51, 0.87) 
3-4.9 1.72 (1.45, 2.05) 1.55 (1.26, 1.90) 1.34 (1.12, 1.61) 1 0.78 (0.63, 0.97) 0.65 (0.51, 0.84) 
5-9.9 1.17 (1.02, 1.34) 1.42 (1.22, 1.65) 1.30 (1.15, 1.49) 1 0.92 (0.80, 1.07) 0.83 (0.71, 0.98) 
≥10 1.03 (0.84, 1.25) 1.31 (1.05, 1.64) 1.17 (0.97, 1.42) 1 0.84 (0.68, 1.03) 0.98 (0.79, 1.21) 
All time 1.87 (1.74, 2.02) 1.69 (1.55, 1.84) 1.44 (1.33, 1.55) 1 0.81 (0.74, 0.89) 0.77 (0.69,0.85) 
  Adjusted mortality rate ratios (95% CI) 
<0.5 2.81 (2.12, 3.71) 1.71 (1.24, 2.37) 1.67 (1.25, 2.25) 1 0.70 (0.46, 1.07) 0.62 (0.38, 1.02) 
0.5-0.9 2.50 (1.80, 3.47) 2.04 (1.41, 2.93) 1.65 (1.18, 2.31) 1 0.59 (0.36, 0.96) 0.35 (0.18, 0.69) 
1-2.9 2.33 (1.95, 2.79) 1.76 (1.44, 2.16) 1.53 (1.28, 1.83) 1 0.72 (0.57, 0.91) 0.72 (0.55, 0.94) 
3-4.9 1.59 (1.31, 1.92) 1.36 (1.10, 1.69) 1.22 (1.02, 1.47) 1 0.80 (0.64, 1.00) 0.70 (0.55, 0.91) 
5-9.9 1.01 (0.87, 1.17) 1.20 (1.02, 1.40) 1.16 (1.02, 1.32) 1 0.96 (0.83, 1.11) 0.92 (0.78, 1.08) 
≥10 0.85 (0.68, 1.05) 1.07 (0.85, 1.35) 1.01 (0.83, 1.22) 1 0.88 (0.71, 1.09) 1.09 (0.88, 1.35) 
All time 1.51 (1.40,1.64) 1.37 (1.25,1.50) 1.26 (1.16,1.36) 1 0.85 (0.78,0.93) 0.84 (0.76,0.93) 
  Adjusted relative mortality rate ratios (95% CI) 
<0.5 3.15 (2.28, 4.36) 1.87 (1.29, 2.72) 1.84 (1.31, 2.59) 1 0.66 (0.39,1.11) 0.52 (0.27, 1.02) 
0.5-0.9 2.91 (1.97, 4.31) 2.38 (1.55, 3.65) 1.80 (1.20, 2.70) 1 0.46 (0.22, 0.94) 0.30 (0.12, 0.75) 
1-2.9 2.78 (2.23, 3.48) 2.01 (1.57, 2.58) 1.66 (1.32, 2.09) 1 0.65 (0.47, 0.91) 0.65 (0.45, 0.93) 
3-4.9 1.74 (1.39, 2.20) 1.42 (1.09, 1.85) 1.31 (1.04, 1.63) 1 0.78 (0.59, 1.03) 0.63 (0.45, 0.90) 
5-9.9 0.99 (0.81, 1.21) 1.27 (1.03, 1.56) 1.20 (1.00, 1.43) 1 0.94 (0.77, 1.14) 0.79 (0.63, 1.00) 
≥10 0.79 (0.55, 1.15) 0.98 (0.65, 1.47) 1.01 (0.73, 1.40) 1 0.79 (0.55, 1.14) 1.12 (0.79, 1.58) 
All time 1.72 (1.56, 1.91) 1.51 (1.35, 1.70) 1.35 (1.22, 1.50) 1 0.80 (0.70,0.91) 0.75 (0.64, 0.86) 
Models were stratified by cohort. Adjusted and relative survival models were adjusted for sex, age, transmission risk group, 
AIDS at baseline, viral load, and year of starting ART. 
CI Confidence Interval 
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